Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01808144 · ClinicalTrials.gov registry record · Phase 3
Lesinurad and Febuxostat Combination Extension Study in Gout
A Phase 3 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 196
- Enrollment target
NCT01808144 is a Phase 3 study that has completed, run by Ardea Biosciences. The registered enrollment target is 196 participants.
The verdict
NCT01808144, a Phase 3 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 196 participants
- Enrollment target
Study Summary
This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with febuxostat over a long-term timeframe.
Interventions
- DRUG lesinurad
- DRUG febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2013-03-01 |
| Est. Completion | 2016-10-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01808144
The ClinicalTrials.gov registry entry for NCT01808144 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lesinurad is the first listed.
NCT01808144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01808144 about?
NCT01808144 is a clinical study titled "Lesinurad and Febuxostat Combination Extension Study in Gout". This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with febuxostat over a long-term timeframe.
What is the current status of trial NCT01808144?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2013-03-01. Estimated completion is 2016-10-06.
What interventions are being tested in trial NCT01808144?
The interventions under investigation include: lesinurad (DRUG), febuxostat (DRUG).
Who is sponsoring clinical trial NCT01808144?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.